Hyundai Bio Science's XAFTY Shows Potential Against Ebola, Hantaviruses

As a leading Korean pharmaceutical company, Hyundai Bio Science is making significant strides in the global fight against infectious diseases. The recent findings regarding XAFTY's potential against Ebola and Hantaviruses, building upon its established efficacy against COVID-19 and dengue, underscore the company's commitment to developing innovative antiviral solutions.

“

We are securing sufficient drug inventory to enable trial applications or emergency supply for infectious disease outbreaks at the request of international organizations or affected countries.

The company's proactive stance in ensuring adequate stock for emergency response highlights its dedication to global health security. This readiness to supply XAFTY for urgent needs, should international organizations or affected nations request it, positions Hyundai Bio Science as a crucial partner in managing potential outbreaks of high-risk infectious diseases.

“

The clinical efficacy of an antiviral drug can be predicted through its IC50 value against the virus. XAFTY, a drug whose safety in humans is being confirmed, needs to be considered as an Ebola treatment.

Professor Davey Smith's endorsement of XAFTY as a potential Ebola treatment, based on its promising IC50 values and confirmed safety in humans, provides strong scientific validation. The company's continued research and development, including ongoing clinical trials for dengue and previous trials for COVID-19, demonstrate a rigorous approach to bringing effective treatments to market. This dedication to scientific rigor and global health makes Hyundai Bio Science a key player to watch in the antiviral drug development landscape.

“

XAFTY is a candidate for a broad-spectrum antiviral drug whose human safety has been confirmed through clinical trials for COVID-19 and dengue. It is a therapeutic candidate for which scientific evidence has been secured to consider additional non-clinical and clinical evaluations in crisis situations involving deadly infectious diseases like Ebola and Hantavirus.